AKYA — Akoya Biosciences Share Price
0.000.00%
Last trade - 00:00- $64.79m
- $107.23m
- $81.67m
- 41
- 29
- 26
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.53 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.9% | ||
| Return on Equity | -180.44% | ||
| Operating Margin | -57.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 42.44 | 54.92 | 74.86 | 96.63 | 81.67 | 90.72 | 103.43 | 14.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. It offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
Directors
- Brian McKelligon PRE (52)
- Joseph Driscoll CFO (56)
- Frederic Pla COO (62)
- Marilee Moy CHO
- Pascal Bamford SVP
- Seth Benson VOP
- Peter Miller VRD
- Niro Ramachandran OTH (46)
- Robert Shepler LED (64)
- Myla Lai-Goldman DRC (63)
- Thomas Raffin DRC (73)
- Garry Nolan IND (59)
- Thomas Schnettler IND (64)
- Matthew Winkler IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 13th, 2015
- Public Since
- April 16th, 2021
- No. of Shareholders
- 24
- No. of Employees
- 205
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 49,836,931
- Address
- 100 Campus Drive, 6Th Floor, MARLBOROUGH, 01762
- Web
- https://www.akoyabio.com/
- Phone
- +1 4157656980
- Auditors
- RSM US LLP
Upcoming Events for AKYA
Q1 2025 Akoya Biosciences Inc Earnings Release
Akoya Biosciences Inc Annual Shareholders Meeting
Q2 2025 Akoya Biosciences Inc Earnings Release
Similar to AKYA
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
Angiodynamics
NASDAQ Global Select Market
FAQ
What is the Akoya Biosciences share price?
As of Today at 19:09 UTC, shares in Akoya Biosciences are trading at $1.30. This share price information is delayed by 15 minutes.
How has the Akoya Biosciences share price performed this year?
Shares in Akoya Biosciences last closed at $1.30 and the price had moved by -65.97% over the past 365 days. In terms of relative price strength the Akoya Biosciences share price has underperformed the S&P500 Index by -68.59% over the past year.
What are the analyst and broker recommendations for Akoya Biosciences?
The overall consensus recommendation for Akoya Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Akoya Biosciences dividend yield?
Akoya Biosciences does not currently pay a dividend.
Does Akoya Biosciences pay a dividend?
Akoya Biosciences does not currently pay a dividend.
When does Akoya Biosciences next pay dividends?
Akoya Biosciences does not currently pay a dividend.
How do I buy Akoya Biosciences shares?
To buy shares in Akoya Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Akoya Biosciences?
As of the previous close price of $1.30, shares in Akoya Biosciences had a market capitalisation of $64.79m.
Where are Akoya Biosciences shares listed?
Here are the trading details for Akoya Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AKYA
What kind of share is Akoya Biosciences?
Based on an overall assessment of its quality, value and momentum Akoya Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Akoya Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Akoya Biosciences is $2.99. That is 130% above the last closing price of $1.30.
Analysts covering Akoya Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.65 for the next financial year.
Find out moreWhat is the trend in the Akoya Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akoya Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -51.06%.
As of the last closing price of $1.30, shares in Akoya Biosciences were trading -44.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Akoya Biosciences PE Ratio?
The Akoya Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Akoya Biosciences?
Akoya Biosciences' management team is headed by:
- Brian McKelligon - PRE
- Joseph Driscoll - CFO
- Frederic Pla - COO
- Marilee Moy - CHO
- Pascal Bamford - SVP
- Seth Benson - VOP
- Peter Miller - VRD
- Niro Ramachandran - OTH
- Robert Shepler - LED
- Myla Lai-Goldman - DRC
- Thomas Raffin - DRC
- Garry Nolan - IND
- Thomas Schnettler - IND
- Matthew Winkler - IND